Jazz Pharmaceuticals JAZZ and partner PharmaMar announced that they have initiated a phase III confirmatory study — LAGOON — to evaluate Zepzelca in patients with relapsed small cell lung cancer ...
Jazz Pharmaceuticals plc JAZZ announced that it enrolled the first patient in IMforte phase III study to evaluate its cancer drug Zepzelca (lurbinectedin) with Roche’s RHHBY Tecentriq (atezolizumab), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results